RAS-Targeting Drugs for Precision Oncology Market Size, Share and Key Players Analysis 2025 to 2034

Report Id: 3074 Pages: 170 Last Updated: 23 December 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of RAS-Targeting Drugs for Precision Oncology Market -

RAS-Targeting Drugs for Precision Oncology by Drug Type -

  • Small Molecule Inhibitors
  • Biologics
  • RNA-Based Therapies
  • Combination Therapies

RAS-Targeting Drugs for Precision Oncology

RAS-Targeting Drugs for Precision Oncology by Target Mutation -

  • KRAS G12C
  • KRAS G12D
  • KRAS G12V, G12R, G12S, G12A
  • HRAS and NRAS
  • Pan-RAS

RAS-Targeting Drugs for Precision Oncology by Indication -

  • Non-Small Cell Lung Cancer (NSCLC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Colorectal Cancer (CRC)
  • Other Cancers (e.g., HNSCC, melanoma, hematologic)

RAS-Targeting Drugs for Precision Oncology by Route of Administration -

  • Oral
  • Intravenous
  • Other Routes

RAS-Targeting Drugs for Precision Oncology by Region-

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global RAS-Targeting Drugs for Precision Oncology Market Snapshot

Chapter 4. Global RAS-Targeting Drugs for Precision Oncology Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on RAS-Targeting Drugs for Precision Oncology Market Trends
4.10. Global RAS-Targeting Drugs for Precision Oncology Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034

Chapter 5. RAS-Targeting Drugs for Precision Oncology Market Segmentation 1: By Drug Type, Estimates & Trend Analysis
5.1. Market Share by Drug Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Type:

5.2.1. Small Molecule Inhibitors
5.2.2. Biologics
5.2.3. RNA-Based Therapies
5.2.4. Combination Therapies

Chapter 6. RAS-Targeting Drugs for Precision Oncology Market Segmentation 2: Target Mutation, Estimates & Trend Analysis
6.1. Market Share by Target Mutation, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Target Mutation:

6.2.1 KRAS G12C
6.2.2 KRAS G12D
6.2.3 KRAS G12V, G12R, G12S, G12A
6.2.4 HRAS and NRAS
6.2.5 Pan-RAS

Chapter 7. RAS-Targeting Drugs for Precision Oncology Market Segmentation 3: By Indication, Estimates & Trend Analysis
7.1. Market Share by Indication, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:

7.2.1. Non-Small Cell Lung Cancer (NSCLC)
7.2.2. Pancreatic Ductal Adenocarcinoma (PDAC)
7.2.3. Colorectal Cancer (CRC)
7.2.4. Other Cancers (e.g., HNSCC, melanoma, hematologic)

Chapter 8. RAS-Targeting Drugs for Precision Oncology Market Segmentation 4: By Route of Administration, Estimates & Trend Analysis
8.1. Market Share by Route of Administration, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:

8.2.1. Oral
8.2.2. Intravenous
8.2.3. Other Routes

Chapter 9. RAS-Targeting Drugs for Precision Oncology Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global RAS-Targeting Drugs for Precision Oncology Market, Regional Snapshot 2024 & 2034
9.2. North America

9.2.1. North America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

9.2.1.1. US
9.2.1.2. Canada

9.2.2. North America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
9.2.3. North America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Target Mutation, 2021-2034
9.2.4. North America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.2.5. North America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034

9.3. Europe

9.3.1. Europe RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe

9.3.2. Europe RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
9.3.3. Europe RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Target Mutation, 2021-2034
9.3.4. Europe RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.3.5. Europe RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034

9.4. Asia Pacific

9.4.1. Asia Pacific RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific

9.4.2. Asia Pacific RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
9.4.3. Asia Pacific RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Target Mutation, 2021-2034
9.4.4. Asia Pacific RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.4.5. Asia Pacific RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034

9.5. Latin America

9.5.1. Latin America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America

9.5.2. Latin America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
9.5.3. Latin America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Target Mutation, 2021-2034
9.5.4. Latin America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.5.5. Latin America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034

9.6. Middle East & Africa

9.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa

9.6.2. Middle East & Africa RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
9.6.3. Middle East & Africa RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Target Mutation, 2021-2034
9.6.4. Middle East & Africa RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.6.5. Middle East & Africa RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034

Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles

10.2.1. Amgen

10.2.1.1. Business Overview
10.2.1.2. Key Drug Type/Service Overview
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy

10.2.2. Mirati Therapeutics
10.2.3. Revolution Medicines
10.2.4. Verastem Oncology
10.2.5. Novartis
10.2.6. Kura Oncology
10.2.7. Elicio Therapeutics
10.2.8. Jacobio Pharmaceuticals
10.2.9. Onconova Therapeutics
10.2.10. Targovax
10.2.11. Genfleet Therapeutics
10.2.12. Golden Biotechnology
10.2.13. Roche
10.2.14. Nested Therapeutics
10.2.15. AnBogen
10.2.16. AstraZeneca

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
9044
Security Code field cannot be blank!

Frequently Asked Questions

RAS-Targeting Drugs for Precision Oncology Market Size is predicted to grow with a 11.9% CAGR during the forecast period for 2025-2034.

Amgen, Mirati Therapeutics, Revolution Medicines, Verastem Oncology, Novartis, Kura Oncology, Elicio Therapeutics, Jacobio Pharmaceuticals, Onconova T

Drug Type, Target Mutation, Indication and Route of Administration are the key segments of the RAS-Targeting Drugs for Precision Oncology Market.

North America region is leading the RAS-Targeting Drugs for Precision Oncology Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying